Maternal and Perinatal Outcome in Women with Systemic Lupus Erythematosus: A Retrospective Bicenter Cohort Study
Table 2
Disease activity before, during, and after pregnancy and medication alterations.
Total ()
SLE-aPL ()
SLE + aPL ()
SLE + APS ()
value
SLEDAI < 6 months before pregnancy
2 [0–4]
2 [0–4]
2 [0–4]
3 [2–4]
0.22
SLEPDAI 1st trimester
2 [0–2]
2 [0–2]
2 [0–2]
2 [0.5–2]
0.41
SLEPDAI 2nd trimester
2 [0–2]
2 [0–2]
2 [1–3]
2 [0.5–2]
0.74
SLEPDAI 3rd trimester
2 [0–2]
0 [0–2]
2 [2–4.5]
2 [0.5–5.5]
<0.01
SLEDAI < 6 months postpartum
2 [0–4]
2 [0–4]
2 [0–5]
4 [2–5.5]
0.27
Any flare before, during pregnancy, or postpartum
44/144 (30.6)
35/117 (29.9)
5/14 (35.7)
4/13 (30.8)
0.94
Severe flare before, during pregnancy, or postpartum
5/144 (3.5)
5/117 (4.3)
0/14 (0)
0/13 (0)
1.00
Mild/moderate flare before, during pregnancy, or postpartum
40/144 (27.8)
31/117 (26.5)
5/14 (35.7)
4/13 (30.8)
0.73
<6 months before pregnancy
9/144 (6.3)
8/117 (6.8)
0/14 (0)
1/13 (7.7)
0.67
1st trimester
6/144 (4.2)
5/117 (4.3)
1/14 (7.1)
0/13 (0)
0.72
2nd trimester
14/144 (9.7)
9/117 (7.7)
3/14 (21.4)
2/13 (15.4)
0.11
3rd trimester
7/144 (4.9)
6/117 (5.1)
1/14 (7.1)
0/13 (0)
0.77
<6 months postpartum
20/144 (13.9)
17/117 (14.5)
2/14 (14.3)
1/13 (7.7)
0.91
Medication started or dosage increased during pregnancy
Prednisone
25/144 (17)
22/117 (19)
2/14 (14)
1/13 (8)
0.77
Prednisone
25/144 (17)
22/117 (19)
2/14 (14)
1/13 (8)
0.77
Azathioprine
6/144 (4)
5/117 (4)
1/14 (7)
0/13 (0)
0.72
Hydroxychloroquine
4/144 (3)
1/117 (1)
0/14 (0)
3/13 (23)
<0.01
Data depicted as median [interquartile range] or numbers (%). A woman can flare multiple times before or during pregnancy or postpartum. SLE: systemic lupus erythematosus; aPL: antiphospholipid antibodies; APS: antiphospholipid syndrome; SLEDAI: SLE disease activity index; SLEPDAI: SLE disease activity index adjusted for pregnancy.
